Indivior PLC(INDV) - 2024 Q1 - Quarterly Report

April 25, 2024 Delivered Double-Digit Net Revenue Growth in Q1 2024; FY 2024 Guidance Reconfirmed Comment by Mark Crossley, CEO of Indivior PLC "Our first quarter results reflect continued double-digit top-line momentum led by SUBLOCADE (buprenorphine extended-release). The underlying demand for this transformative treatment for moderate-to-severe opioid use disorder (OUD) remains strong and our strategy to expand prescribing in the justice system is delivering excellent results. SUBLOCADE's reported growth ...